Bosh sahifa500660 • BOM
add
GlaxoSmithKline Pharmaceuticals Ltd
Yopilish kursi
2 569,45 ₹
Kunlik diapazon
2 487,55 ₹ - 2 586,00 ₹
Yillik diapazon
1 825,05 ₹ - 3 087,95 ₹
Bozor kapitalizatsiyasi
424,73 mlrd INR
Oʻrtacha hajm
16,24 ming
Narx/foyda
49,71
Dividend daromadliligi
1,28%
Asosiy maydon
NSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (INR) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 9,49 mlrd | 17,90% |
Joriy xarajat | 3,17 mlrd | 10,32% |
Sof foyda | 2,30 mlrd | 402,80% |
Sof foyda marjasi | 24,21 | 326,23% |
Har bir ulushga tushum | — | — |
EBITDA | 2,84 mlrd | 34,40% |
Amaldagi soliq stavkasi | 25,39% | — |
Balans
Jami aktivlari
Jami passivlari
| (INR) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 21,11 mlrd | 31,49% |
Jami aktivlari | — | — |
Jami passivlari | — | — |
Umumiy kapital | 16,73 mlrd | — |
Tarqatilgan aksiyalar | 169,40 mln | — |
Narxi/balansdagi bahosi | 26,44 | — |
Aktivlardan daromad | — | — |
Kapitaldan daromad | 40,46% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (INR) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 2,30 mlrd | 402,80% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
Tashkil etilgan
13-noy, 1924
Xodimlar soni
3 211
